Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Potential impact of sorafenib on the survival benefit of liver transplantation for hepatocellular carcinoma.

Vitale A, Lombardi G, Ramirez Morales R, Cillo U.

Dig Liver Dis. 2012 May;44(5):361-2. doi: 10.1016/j.dld.2012.02.014. Epub 2012 Mar 14. No abstract available.

PMID:
22424640
2.

Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation.

Weinmann A, Niederle IM, Koch S, Hoppe-Lotichius M, Heise M, Düber C, Schuchmann M, Otto G, Galle PR, Wörns MA.

Dig Liver Dis. 2012 May;44(5):432-7. doi: 10.1016/j.dld.2011.12.009. Epub 2012 Jan 20.

PMID:
22265328
3.

[Prospect of hepatocellular carcinoma in 2008].

Ye SL.

Zhonghua Gan Zang Bing Za Zhi. 2009 Jan;17(1):7-9. Chinese. No abstract available.

PMID:
19391280
4.
5.

Sorafenib for recurrent hepatocellular carcinoma after liver transplantation.

Yoon DH, Ryoo BY, Ryu MH, Lee SG, Hwang S, Suh DJ, Lee HC, Kim TW, Ahn CS, Kim KH, Moon DB, Kang YK.

Jpn J Clin Oncol. 2010 Aug;40(8):768-73. doi: 10.1093/jjco/hyq055. Epub 2010 May 21.

PMID:
20494947
6.

Sorafenib before liver transplantation for hepatocellular carcinoma: risk or give up.

Di Benedetto F, Tarantino G, Montalti R, Ballarin R, D'Amico G, Berretta M, Gerunda GE.

Transpl Int. 2011 Nov;24(11):e97; author reply e98-9. doi: 10.1111/j.1432-2277.2011.01329.x. Epub 2011 Sep 13. No abstract available.

7.

Hepatocellular carcinoma: sorafenib before liver transplantation?

Braillon A.

Hepatology. 2010 Jun;51(6):2232-3. doi: 10.1002/hep.23439. No abstract available.

PMID:
20041410
8.

Liver transplantation in a patient treated by sorafenib for hepatocellular carcinoma.

Borentain P, Gregoire E, Hardwigsen J, Garcia S, Durieux O, Le Treut YP, Gérolami R.

Clin Res Hepatol Gastroenterol. 2011 Mar;35(3):234-6. doi: 10.1016/j.clinre.2010.12.007. Epub 2011 Feb 22.

PMID:
21345761
9.

mTOR inhibitors and sorafenib for recurrent heptocellular carcinoma after orthotopic liver transplantation.

Waidmann O, Hofmann WP, Zeuzem S, Trojan J.

J Hepatol. 2011 Feb;54(2):396-8. doi: 10.1016/j.jhep.2010.08.038. Epub 2010 Nov 10. No abstract available.

10.

[Clinical analysis of the treatment:transcatheter arterial chemoembolization combined with sorafenib in advanced hepatocellular carcinoma].

Li Y, Huang JW, Lu LG, Shao PJ, Hu BS, Huang GM, Wei ZG, Zhang L.

Zhonghua Yi Xue Za Zhi. 2010 Aug 17;90(31):2187-92. Chinese.

PMID:
21029658
11.

Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.

Gomez-Martin C, Bustamante J, Castroagudin JF, Salcedo M, Garralda E, Testillano M, Herrero I, Matilla A, Sangro B.

Liver Transpl. 2012 Jan;18(1):45-52. doi: 10.1002/lt.22434.

12.

Treating hepatocellular carcinoma with sorafenib in liver transplant patients: an initial experience.

Saidi RF, Shah SA, Rawson AP, Grossman S, Piperdi B, Bozorgzadeh A.

Transplant Proc. 2010 Dec;42(10):4582-4. doi: 10.1016/j.transproceed.2010.09.147.

PMID:
21168742
13.

Review article: the management of hepatocellular carcinoma.

Cabrera R, Nelson DR.

Aliment Pharmacol Ther. 2010 Feb 15;31(4):461-76. doi: 10.1111/j.1365-2036.2009.04200.x. Epub 2009 Nov 19. Review.

14.

Downstaging of hepatocellular carcinoma prior to liver transplant: is there a role for adjuvant sorafenib in locoregional therapy?

Vagefi PA, Hirose R.

J Gastrointest Cancer. 2010 Dec;41(4):217-20. doi: 10.1007/s12029-010-9163-y. Review.

15.

Markedly effective local control of hepatocellular carcinoma with a poor prognosis by combined multimodal therapy with sorafenib as a neoadjuvant approach.

Bathaix F, Marion D, Cuinet M, Maillard E, Zoulim F, Mornex F, Merle P.

Gastroenterol Clin Biol. 2010 Apr-May;34(4-5):314-8. doi: 10.1016/j.gcb.2010.01.015. Epub 2010 Mar 5.

16.

Recurrent hepatocellular carcinoma in liver transplant recipients: parameters affecting time to recurrence, treatment options and survival in the sorafenib era.

Pfiffer TE, Seehofer D, Nicolaou A, Neuhaus R, Riess H, Trappe RU.

Tumori. 2011 Jul-Aug;97(4):436-41. doi: 10.1700/950.10394.

PMID:
21989430
17.

TACE with or without systemic therapy?

Dufour JF.

J Hepatol. 2012 Jun;56(6):1224-5. doi: 10.1016/j.jhep.2012.02.011. Epub 2012 Mar 5. No abstract available.

18.

Major achievements in hepatocellular carcinoma.

Bruix J, Llovet JM.

Lancet. 2009 Feb 21;373(9664):614-6. doi: 10.1016/S0140-6736(09)60381-0. No abstract available.

PMID:
19231618
19.

Transarterial therapies for hepatocellular carcinoma (HCC): a long way towards standardization.

Tsochatzis EA, Meyer T, O'Beirne J, Burroughs AK.

J Hepatol. 2013 Jan;58(1):194. doi: 10.1016/j.jhep.2012.08.028. Epub 2012 Oct 6. No abstract available.

20.

Reply to: "Transarterial therapies for hepatocellular carcinoma (HCC): a long way towards standardization".

Park JW, Kim HB, Lee IJ.

J Hepatol. 2013 Jan;58(1):195. doi: 10.1016/j.jhep.2012.09.033. Epub 2012 Oct 6. No abstract available.

Supplemental Content

Support Center